Blister
Pemphigus Vulgaris
search
Pemphigus Vulgaris
See Also
Bullous Disease
Pemphigus
Epidemiology
Incidence
: 0.5 to 3.2 cases per 100,000 (U.S.)
Higher
Incidence
in Ashkenazi jews
Mean age of onset: 40 to 60 years old
Men and women are affected equally
Definition
Most common, severe and deeper form of
Pemphigus
Risk Factors
Ashkenazi jewish descent
Autoimmune Condition
(e.g. SLE,
Rheumatoid Arthritis
,
Myasthenia Gravis
)
Triggers
See medications below
Burn Injury
Infections
Pathophysiology
IgG against
Keratinocyte
cell surface molecules (desmoglein 1 and 3) in skin and mucosa
Antibody
binding results in
Acantholysis
(loss of cell to cell adhesion)
May be unmasked by certain medications (e.g.
Penicillin
,
NSAID
s,
ACE Inhibitor
s, Pyrazolones)
See
Drug-Triggered Pemphigus
Symptoms
Painful, often burning lesions (may be pruritic)
Oral symptoms with mucosal involvement
Dysphagia
Hoarseness
Epistaxis
Constitutional symptoms
Weakness
Malaise
Signs
Mucosal sites of involvement
Painful
Gingiva
l erosions (50-70% of patients)
May precede skin bullae by months
Conjunctiva
and
Esophagus
may also be involved
Flaccid bullae (difficult to see due to flaccidity)
Clear fluid filled
Blister
s with thin walls that easily rupture, developing into painful erosions
Blister
s overly an erythematous base
Nikolsky Sign
positive
Painful erosions (most common skin finding)
May bleed easily
Crust
ing is often present
Lesions are painful rather than pruritic (contrast with
Bullous Pemphigoid
)
Skin Sites of involvement
Face
Scalp
Upper body
Intertriginous areas (axillae, groin)
Umbilicus
Nails (
Subungual Hematoma
,
Chronic Paronychia
)
Labs
Biopsy of bulla margin
Suprabasilar
Blister
(above
Basal Cell Layer
)
Acantholysis
Rounded basal cells appear as row of tombstones
Eosinophil
ic infiltrates
Direct Immunofluorescence
Intercellular deposits of IgG and C3 on
Keratinocyte
s
Course
Onset on
Oral Mucosa
Skin lesions follow
Oral Lesion
s by months
Localized skin involvement for 6-12 months
Gene
ralized involvement then ensues
Associated Conditions
Thymoma (and
Myasthenia Gravis
)
Possible complications of immunosuppressive therapy
Kaposi's Sarcoma
Lymph
oreticular malignancy
Variants
Pemphigus Vegetans
(
Familial Benign Pemphigus
)
Management
Immunosuppressive Therapy
Disposition
Most patients are treated out of the hospital
Admit patients with extensive bullae and erosions for IV fluids and
Electrolyte
management
Prednisone
1 mg/kg/day
Reduce dose by 50% when no new
Blister
formation
Gradually taper to minimum effective dose
Topical Corticosteroid
s may also be used as an adjunct
Adjunctive
Immunosuppressive Drug
s
Methotrexate
Azathioprine
(
Imuran
)
Cyclophosphamide
(
Cytoxan
)
Mycophenolate Mofetil
(
Cellcept
)
Other measures in severe cases
Plasmapheresis
Complications
Secondary infection (due to immunosuppressive therapy)
Prognosis
Mortality highest in first few years (up to 10%)
Complications of
Corticosteroid
s
References
Long (2016) Crit Dec Emerg Med 30(7):3-10
Cotran (1999) Robbins Pathology, p. 1202
Bickle (2002) Am Fam Physician 65(9):1861-70 [PubMed]
Cotell (2000) Am J Emerg Med 18(3):288-99 [PubMed]
Rye (1997) Am Fam Physician 55(8): 2709-18 [PubMed]
Type your search phrase here